TandemAI Revenue and Competitors
Estimated Revenue & Valuation
- TandemAI's estimated annual revenue is currently $13.8M per year.
- TandemAI's estimated revenue per employee is $155,000
Employee Data
- TandemAI has 89 Employees.
- TandemAI grew their employee count by 17% last year.
TandemAI's People
Name | Title | Email/Phone |
---|---|---|
1 | CTO | Reveal Email/Phone |
2 | Director, Head Scientific Visualization | Reveal Email/Phone |
3 | Director, Business Development | Reveal Email/Phone |
4 | Director, Computational Chemistry | Reveal Email/Phone |
5 | Senior Software Engineer | Reveal Email/Phone |
6 | Senior Investigator | Reveal Email/Phone |
TandemAI Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | 0% | N/A | N/A |
#2 | $3.7M | 24 | 41% | $44M | N/A |
#3 | $6.2M | 40 | -7% | N/A | N/A |
#4 | $42M | 271 | -1% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $10M | N/A |
#6 | $2.5M | 16 | 0% | N/A | N/A |
#7 | $7.5M | 45 | 0% | $51.6M | N/A |
#8 | $0.2M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 26 | -16% | $3.3M | N/A |
#10 | $3.7M | 24 | 4% | N/A | N/A |
What Is TandemAI?
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution. TandemAI has built its networked platform from the ground up in the U.S. and China to increase the speed of drug discovery and deliver cost-effective opportunities to its partners and to the global scientific community.
keywords:N/AN/A
Total Funding
89
Number of Employees
$13.8M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $12.9M | 89 | -14% | N/A |
#2 | $28.9M | 89 | -3% | N/A |
#3 | $21.6M | 89 | -25% | $66.2M |
#4 | $15M | 89 | 10% | N/A |
#5 | $15M | 89 | -14% | N/A |